OmniAb signs up to $370M licensing deal with Eli Lilly for ion channel program
What it means
- What to watch: Policy moves the whole healthcare aisle; trial data moves one company. Knowing which kind of story this is helps.
- How the stock is trading: $OABI -2.51% in the latest session.
- Timing: It landed before the opening bell — early risers had it with their coffee, and the next session was the first that could react.
Where the stock stands
$OABI last changed hands at $4.66, -2.51% on the session, 14% below its 52-week high of $5.43 and 258% above its low of $1.30 — in the upper part of the range. Over the year it has ranged 318% from low to high: a very wide band; big swings are routine for this one, not news. These are latest-session quotes, not live prices — the live tape is on the $OABI page.
The bigger picture
In healthcare, the calendar is the catalyst — trial readouts, FDA decisions and pricing rules. One result can move a single drugmaker sharply; a policy change moves the whole aisle. On Wook's supply-chain scanner, Health Care reads calm today — no unusual stress in the filings and disclosures it watches. The scanner equivalent of a quiet night shift.
Coming up
$OABI earnings in 6 days. These were on the calendar before this story and are not caused by it, but the nearest is close enough that the next hard numbers on this company are almost here.
What to watch next
For the receipts, the $OABI page has the full chart, the filings and the valuation model these figures come from. Want the facts without the spin? Read how two or three outlets frame the same story — where they agree is the news, where they differ is the angle. Wook AI, above, can pull live figures and run the numbers on request — how far $OABI is from its high, or how this week's coverage compares.
How this analysis was made
Seeking Alpha published it, and Wook filed it under Healthcare & Pharma. No strongly worded term either way, so it reads neutral at low severity — a factual headline rather than a charged one. It was matched to $OABI. It carried $370 million, shown as published and not recalculated. The publisher gave no preview text, and nothing has been written in to fill the gap.
The tone and severity labels come from a fixed word list — no editor, no AI, no crystal ball — so they describe how a story is worded, not what happens next. They are not a forecast or a recommendation, and a same-day move does not mean this story caused it. Not investment advice.
Discussion
No one has weighed in yet. Start the discussion on this story.
What happened after this published
Seeking Alpha published this on August 17, 2026. $OABI has moved +21.99% ($3.82 to $4.66). Measured from the first print available after publication, against the latest available quote. This comparison does not isolate the story's effect.